GURU.Markets stock price, segment price, and overall market index valuation
The company's share price Iterum Therapeutics plc
Iterum Therapeutics is a biopharmaceutical company focused on antibiotic development. Its stock price reflects the struggle to secure FDA approval for its lead drug, a typical story for single-product biotechs.
Share prices of companies in the market segment - Pharma infections
Iterum Therapeutics is a pharmaceutical company focused on developing an oral antibiotic for the treatment of urinary tract infections caused by resistant bacteria. We have classified it in the Pharma: Infections category. The chart below shows how the market views the fight against superbugs.
Broad Market Index - GURU.Markets
Iterum Therapeutics is an Irish pharmaceutical company focused on developing oral antibiotics for the treatment of multidrug-resistant infections. It is a component of the GURU.Markets index, and the chart below shows how its stock compares to the overall market trend.
Change in the price of a company, segment, and market as a whole per day
ITRM - Daily change in the company's share price Iterum Therapeutics plc
For Iterum Therapeutics plc, an antibiotic developer, daily price changes are a measure of enormous volatility. This metric reflects extreme sensitivity to clinical trial data and FDA decisions, and is key to risk assessment.
Daily change in the price of a set of shares in a market segment - Pharma infections
Iterum Therapeutics plc is a biotech company. This chart demonstrates the extreme volatility of the sector. Comparison with ITRM, which focuses on combating antibiotic-resistant bacteria, helps to assess it as a high-risk asset.
Daily change in the price of a broad market stock, index - GURU.Markets
Iterum Therapeutics is a pharmaceutical company specializing in infectious diseases. Its shares are driven by news about the development of new antibiotics. This dynamic, specific to the pharmaceutical industry, creates fluctuations that contribute to overall volatility.
Dynamics of market capitalization of the company, segment and the market as a whole over 12 months
Annual dynamics of the company's market capitalization Iterum Therapeutics plc
For Iterum Therapeutics plc, year-over-year performance is a story of its battle to secure approval for a new antibiotic. Its market capitalization over the next 12 months is fundamentally dependent on FDA decisions. Obtaining approval for its oral drug for the treatment of complex urinary tract infections will be a fundamental breakthrough for the company after previous setbacks.
Annual dynamics of market capitalization of the market segment - Pharma infections
Iterum Therapeutics plc is a late-stage biopharmaceutical company developing antibiotics. Its stock price is entirely dependent on FDA regulatory decisions. The chart reflects the high risks and binary nature of the outcome for companies dependent on a single key product.
Annual dynamics of market capitalization of broad market stocks, index - GURU.Markets
Iterum Therapeutics is a clinical-stage biotech whose fate depends on scientific breakthroughs, not the state of the economy. Its stock price reflects investor hopes for the success of new drug trials. The company's chart exists in a world of its own, where the main events are data releases.
Dynamics of market capitalization of the company, segment and the market as a whole for the month
Monthly dynamics of the company's market capitalization Iterum Therapeutics plc
Iterum Therapeutics is a late-stage biopharmaceutical company. Its monthly performance is extremely sensitive to regulatory decisions. FDA news regarding its antibiotic can cause multiple price changes in a short period of time.
Monthly dynamics of market capitalization of the market segment - Pharma infections
Iterum Therapeutics is a pharmaceutical company developing antibiotics to combat drug-resistant bacteria. This is a critically important yet commercially challenging area. The dynamics of the pharmaceutical sector provide a context for Iterum's efforts to bring a new drug to market, addressing one of the most pressing challenges in modern healthcare.
Monthly dynamics of market capitalization of broad market stocks, index - GURU.Markets
Iterum Therapeutics plc is a clinical-stage pharmaceutical company focused on developing a new antibiotic for the treatment of complex infections. Its fate depends on regulatory decisions and clinical data. The broader market chart provides a backdrop to understand how its battle for FDA approval and potential to combat superbugs have impacted its stock.
Dynamics of market capitalization of the company, segment and the market as a whole for the week
Weekly dynamics of the company's market capitalization Iterum Therapeutics plc
Iterum Therapeutics is a biopharmaceutical company developing antibiotics. Its weekly stock price is highly volatile and depends on FDA decisions, which are binary events for the company. A regulatory approval or rejection could cause the stock to rise or fall multiple times.
Weekly dynamics of market capitalization of the market segment - Pharma infections
Iterum Therapeutics is a biopharmaceutical company developing antibiotics. Its weekly stock price is highly volatile and depends on FDA decisions, which are binary events for the company. A regulatory approval or rejection could cause the stock to rise or fall multiple times.
Weekly dynamics of market capitalization of stocks of the broad market, index - GURU.Markets
Shares of Iterum, a biotech company, live in a world of their own. Their performance is determined by FDA decisions. A chart comparing the stock to the S&P 500 clearly demonstrates how the stock can rise or fall on company-specific events, completely ignoring the broader market.
Market capitalization of the company, segment and market as a whole
ITRM - Market capitalization of the company Iterum Therapeutics plc
Iterum Therapeutics' market capitalization tells the story of a biotech company struggling to secure approval for a new oral antibiotic. Its chart reflects the company's repeated FDA rejections and persistent efforts to finally bring the drug to market. It's a visual representation of the long and arduous journey of drug development.
ITRM - Share of the company's market capitalization Iterum Therapeutics plc within the market segment - Pharma infections
Iterum Therapeutics is a clinical-stage pharmaceutical company focused on developing an oral antibiotic for the treatment of drug-resistant infections. Its market capitalization reflects the potential of this drug. The chart below shows how its share depends on regulatory decisions.
Market capitalization of the market segment - Pharma infections
Iterum Therapeutics is a pharmaceutical company developing a new antibiotic to treat infections caused by resistant bacteria. The chart below shows the total market capitalization of the infectious disease pharmaceutical sector. It reflects the critical need for new antibiotics and the high regulatory barriers.
Market capitalization of all companies included in a broad market index - GURU.Markets
This chart represents the fight against superbugs. Iterum Therapeutics is developing a new antibiotic to treat resistant urinary tract infections. Its volatile price action reflects its long and difficult battle for FDA approval. It's a visualization of all the regulatory risks in the pharmaceutical industry.
Book value capitalization of the company, segment and market as a whole
ITRM - Book value capitalization of the company Iterum Therapeutics plc
Iterum Therapeutics' book value is its financial reserves and the rights to an oral antibiotic for the treatment of complex urinary tract infections. This represents focused scientific capital. The chart shows how the biotech company manages its capital during multiple attempts to obtain FDA approval for its lead drug.
ITRM - Share of the company's book capitalization Iterum Therapeutics plc within the market segment - Pharma infections
Iterum Therapeutics is a pharmaceutical company developing antibiotics. Its assets are intellectual property. The chart shows the minimal share in physical assets, as its value lies in the potential of its drugs.
Market segment balance sheet capitalization - Pharma infections
Antibiotic development, as the BCap_Ges chart for biotech shows, is a science-intensive industry. Iterum Therapeutics operates in this environment, where capital is invested in clinical research to combat resistant infections rather than in building factories.
Book value of all companies included in the broad market index - GURU.Markets
Iterum Therapeutics' assets are not its factories, but rather the capital and intellectual property associated with its oral antibiotic. This book value is the financial foundation that allows the company to secure regulatory approval and prepare for the production of a real, tangible drug.
The ratio of market capitalization to book capitalization of a company, segment, and the market as a whole
Market capitalization to book capitalization ratio - Iterum Therapeutics plc
Iterum Therapeutics is a pharmaceutical company developing antibiotics. This is a critically important but commercially challenging area. Its market capitalization will depend entirely on the FDA's decision on its drug. Its MvsBCap chart is a story of its struggle for approval in a sector unpopular with investors due to pricing issues.
Market to book capitalization ratio in a market segment - Pharma infections
Iterum Therapeutics is a pharmaceutical company developing antibiotics. Its value depends on the success of its drugs in the fight against drug-resistant bacteria. The chart shows how investors value its portfolio in this critical area of medicine.
Market to book capitalization ratio for the market as a whole
Iterum Therapeutics is a pharmaceutical company developing a new antibiotic to combat drug-resistant bacteria. Its market value depends almost entirely on its success in obtaining regulatory approval. This chart shows how investors assess the chances of success and the urgent need for new antibiotics.
Debts of the company, segment and market as a whole
ITRM - Company debts Iterum Therapeutics plc
Iterum Therapeutics, a clinical-stage biopharmaceutical company focused on developing new antibiotics, is devoting its entire capital to R&D and regulatory affairs. Combating drug-resistant bacteria is a global priority, but it carries significant financial risk. This chart shows how the company funds its important yet complex mission.
Market segment debts - Pharma infections
Iterum Therapeutics is a clinical-stage pharmaceutical company specializing in developing antibiotics to combat drug-resistant bacteria. This area is critical to healthcare but commercially challenging. The chart shows how the company is raising capital to fund its costly clinical trials.
Market debt in general
Debt to book value of the company, segment and market as a whole
The company's debt to book capitalization ratio Iterum Therapeutics plc
Iterum Therapeutics, a pharmaceutical company developing new antibiotics to combat drug-resistant bacteria, shows its reliance on debt to finance clinical trials. High debt poses a significant risk, as failure to obtain regulatory approval could make it impossible to service.
Market segment debt to market segment book capitalization - Pharma infections
Iterum Therapeutics is a pharmaceutical company focused on developing new antibiotics to combat drug-resistant bacteria. This chart shows the sector's debt burden, helping to understand how the company finances its clinical trials in a critically important yet commercially challenging area of medicine.
Debt to book value of all companies in the market
Iterum Therapeutics plc is a pharmaceutical company focused on developing antibiotics to combat multidrug-resistant pathogens. The overall debt level, shown in this chart, impacts the availability of financing. For a company whose key product is undergoing regulatory approval, a stable investment climate is vital.
P/E of the company, segment and market as a whole
P/E - Iterum Therapeutics plc
This chart from Iterum Therapeutics, a biopharmaceutical company battling drug-resistant bacteria, shows investor sentiment for its antibiotic. The dynamics reflect hopes and doubts regarding its regulatory approval and commercial potential for treating complex urinary tract infections.
P/E of the market segment - Pharma infections
This chart shows the average P/E valuation for the pharmaceutical industry, where Iterum Therapeutics fights infections. This metric serves as a benchmark for assessing the premium the market is willing to pay for the company's antibiotics, which address the problem of growing bacterial resistance.
P/E of the market as a whole
Iterum Therapeutics is a pharmaceutical company developing a new antibiotic to treat complex urinary tract infections caused by resistant bacteria. This chart shows biotech sentiment. It helps understand how the market views the company's chances of receiving FDA approval after previous failures and the need for new antibiotics to combat superbugs.
Future P/E of the company, segment and market as a whole
Future (projected) P/E of the company Iterum Therapeutics plc
Iterum Therapeutics is a pharmaceutical company developing a new antibiotic for the treatment of infections caused by drug-resistant bacteria. Its future depends on regulatory approval. This chart reflects analysts' expectations regarding the FDA's decision and the commercial potential of the new antibiotic.
%20P%2FE%20Iterum%20Therapeutics%20plc&width=1500&height=450&colorIndex=35&filename=GURU_Markets_-_Chart-of-the-companys-future-projected-PE-Iterum-Therapeutics-plc&v=1772671931744 "Chart of the company's future (projected) P/E Iterum Therapeutics plc")
Future (projected) P/E of the market segment - Pharma infections
Iterum Therapeutics is a pharmaceutical company focused on developing antibiotics to treat infections caused by multidrug-resistant bacteria. This chart shows how its future revenue expectations compare to the industry average, reflecting the urgent need for new antibiotics and the challenges of obtaining their approval.
%20P%2FE%20graph%20of%20the%20market%20segment%20-%20Pharma%20infections&width=1500&height=450&colorIndex=36&filename=GURU_Markets_-_Future-projected-PE-graph-of-the-market-segment-Pharma-infections&v=1772671931810 "Future (projected) P/E graph of the market segment - Pharma infections")
Future (projected) P/E of the market as a whole
Iterum Therapeutics is a pharmaceutical company developing antibiotics to combat drug-resistant bacteria. This is a significant medical problem. This chart, showing the overall market appetite for risk, influences valuations and capital availability for biotech companies. Investor optimism is helping Iterum fund clinical trials.
%20P%2FE%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=37&filename=GURU_Markets_-_Chart-of-the-future-projected-PE-of-the-market-as-a-whole&v=1772671931848 "Chart of the future (projected) P/E of the market as a whole")
Profit of the company, segment and market as a whole
Company profit Iterum Therapeutics plc
Iterum Therapeutics plc is a pharmaceutical company developing a new antibiotic for the treatment of complex infections. Its financial situation is shaped by the struggle to obtain FDA approval. This chart shows how clinical trial setbacks and regulatory hurdles affect a company whose fate hinges on a single drug.
Profit of companies in the market segment - Pharma infections
Iterum Therapeutics is a pharmaceutical company developing a new antibiotic for the treatment of urinary tract infections caused by resistant bacteria. The problem of antibiotic resistance makes such developments critical. This chart illustrates the overall dynamics of the pharmaceutical industry, where the development of new antibiotics is a complex yet vital task.
Overall market profit
Iterum Therapeutics is a pharmaceutical company developing antibiotics. The problem of antibiotic resistance is enormous, but the commercial market for new drugs is challenging. The overall economic situation, reflected in the graph, influences the willingness of governments and healthcare systems to invest in solving this problem.
Future (predicted) profit of the company, segment and market as a whole
Future (projected) profit of the company Iterum Therapeutics plc
Iterum Therapeutics is a pharmaceutical company developing a new antibiotic to treat infections caused by drug-resistant bacteria, a serious global health problem. This chart shows analysts' assessments of the approval and commercial success of this urgently needed drug.
%20profit%20of%20the%20company%20Iterum%20Therapeutics%20plc&width=1500&height=450&colorIndex=41&filename=GURU_Markets_-_Graph-of-future-projected-profit-of-the-company-Iterum-Therapeutics-plc&v=1772671932011 "Graph of future (projected) profit of the company Iterum Therapeutics plc")
Future (predicted) profit of companies in the market segment - Pharma infections
Iterum Therapeutics is a pharmaceutical company developing a new oral antibiotic for the treatment of urinary tract infections caused by drug-resistant bacteria. This chart shows profitability forecasts for the pharmaceutical sector. It reflects the urgent global need for new antibiotics to combat the growing threat of antimicrobial resistance.
%20profits%20of%20companies%20in%20a%20market%20segment%20-%20Pharma%20infections&width=1500&height=450&colorIndex=42&filename=GURU_Markets_-_Graph-of-future-predicted-profits-of-companies-in-a-market-segment-Pharma-infections&v=1772671932162 "Graph of future (predicted) profits of companies in a market segment - Pharma infections")
Future (predicted) profit of the market as a whole
Iterum Therapeutics is a pharmaceutical company developing a new antibiotic to combat drug-resistant bacteria. Its success depends on regulatory approval and commercialization. This schedule, reflecting overall market sentiment, impacts the availability of capital needed to complete clinical trials and bring the product to market.
%20profits%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=43&filename=GURU_Markets_-_Chart-of-future-predicted-profits-of-the-market-as-a-whole&v=1772671932178 "Chart of future (predicted) profits of the market as a whole")
P/S of the company, segment and market as a whole
P/S - Iterum Therapeutics plc
Iterum Therapeutics is a biopharmaceutical company developing antibiotics. This chart shows how the market views its potential. The price-to-revenue ratio reflects the urgent need for new antibiotics and the belief that its drug will be approved and gain traction.
P/S market segment - Pharma infections
Iterum Therapeutics plc is a pharmaceutical company specializing in the development of antibiotics for the treatment of infections caused by multidrug-resistant pathogens. This chart shows the average revenue estimate for the pharmaceutical sector. It helps understand how investors assess the potential revenue of Iterum's products in a market with a high demand for new antibiotics.
P/S of the market as a whole
Iterum Therapeutics is a pharmaceutical company focused on developing a new antibiotic for the treatment of complex urinary tract infections caused by resistant bacteria. Their success depends on FDA approval. This chart provides a general revenue metric that can be used to assess how the market values companies tackling the problem of antibiotic resistance.
Future P/S of the company, segment and market as a whole
Future (projected) P/S of the company Iterum Therapeutics plc
Iterum Therapeutics is a pharmaceutical company developing a new antibiotic for the treatment of infections caused by drug-resistant bacteria. This chart reflects investor expectations for its drug. The valuation depends entirely on its regulatory approval and its ability to address the pressing problem of antibiotic resistance.
%20P%2FS%20Iterum%20Therapeutics%20plc&width=1500&height=450&colorIndex=47&filename=GURU_Markets_-_The-graph-of-the-companys-future-projected-PS-Iterum-Therapeutics-plc&v=1772671932375 "The graph of the company's future (projected) P/S Iterum Therapeutics plc")
Future (projected) P/S of the market segment - Pharma infections
Iterum Therapeutics is a clinical-stage pharmaceutical company developing a new antibiotic for the treatment of infections caused by drug-resistant bacteria. This chart shows how the market is pricing its lead drug in the important but complex field of antibiotic development.
%20P%2FS%20market%20segment%20graph%20-%20Pharma%20infections&width=1500&height=450&colorIndex=48&filename=GURU_Markets_-_Future-projected-PS-market-segment-graph-Pharma-infections&v=1772671932424 "Future (projected) P/S market segment graph - Pharma infections")
Future (projected) P/S of the market as a whole
Iterum Therapeutics is a pharmaceutical company developing an antibiotic to treat infections caused by resistant bacteria. This chart, reflecting the overall investment climate, is important for the company. Market optimism facilitates the funding Iterum needs to conduct clinical trials and obtain regulatory approval for its drug.
%20P%2FS%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=49&filename=GURU_Markets_-_Chart-of-the-future-projected-PS-of-the-market-as-a-whole&v=1772671932462 "Chart of the future (projected) P/S of the market as a whole")
Sales of the company, segment and market as a whole
Company sales Iterum Therapeutics plc
Iterum Therapeutics is a pharmaceutical company focused on developing antibiotics to combat multidrug-resistant bacteria. This chart shows its financial flows, which currently come from research funding rather than commercial sales. It illustrates investments in a critical area of medicine—the fight against superbugs.
Sales of companies in the market segment - Pharma infections
Iterum Therapeutics plc is a pharmaceutical company focused on the development and commercialization of antibiotics for the treatment of infections caused by multidrug-resistant pathogens. Its business is centered around its flagship product, which is its core segment. This chart shows the financial flows associated with this key drug.
Overall market sales
Iterum Therapeutics plc is a pharmaceutical company developing a new antibiotic for the treatment of infections caused by resistant bacteria. Antibiotic resistance is one of the most serious threats to global healthcare. Iterum's success depends on clinical data and could provide physicians with a new, important weapon in the fight against superbugs.
Future sales volume of the company, segment and market as a whole
Future (projected) sales of the company Iterum Therapeutics plc
Iterum Therapeutics is a pharmaceutical company focused on developing a new antibiotic for the treatment of infections caused by multidrug-resistant bacteria. Its future sales projections are dependent on FDA approval and a successful commercial launch. This is a bet on solving one of the most pressing problems in modern healthcare.
%20sales%20of%20the%20company%20Iterum%20Therapeutics%20plc&width=1500&height=450&colorIndex=53&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-the-company-Iterum-Therapeutics-plc&v=1772671932584 "Schedule of future (projected) sales of the company Iterum Therapeutics plc")
Future (projected) sales of companies in the market segment - Pharma infections
Iterum Therapeutics is a pharmaceutical company developing a new antibiotic to treat infections caused by drug-resistant bacteria. This chart shows expectations for the infectious diseases sector. It helps assess how acute the problem of antibiotic resistance is, according to analysts.
%20sales%20of%20companies%20in%20the%20market%20segment%20-%20Pharma%20infections&width=1500&height=450&colorIndex=54&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-companies-in-the-market-segment-Pharma-infections&v=1772671932615 "Schedule of future (projected) sales of companies in the market segment - Pharma infections")
Future (projected) sales of the market as a whole
Iterum Therapeutics, a pharmaceutical company developing antibiotics, will see demand for its future product depend on the problem of antibiotic resistance and the willingness of healthcare systems to pay for new solutions. This chart of overall sales forecasts reflects the economic conditions affecting healthcare budgets.
%20sales%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=55&filename=GURU_Markets_-_Schedule-of-future-predicted-sales-of-the-market-as-a-whole&v=1772671932626 "Schedule of future (predicted) sales of the market as a whole")
Marginality of the company, segment and market as a whole
Company marginality Iterum Therapeutics plc
Iterum Therapeutics plc is a clinical-stage pharmaceutical company specializing in the development of antibiotics for the treatment of infections caused by multidrug-resistant pathogens. This chart reflects its financial position, where high clinical trial costs and approvals are key to commercializing a life-saving drug.
Market segment marginality - Pharma infections
Iterum Therapeutics is a pharmaceutical company focused on developing antibiotics to combat drug-resistant bacteria. This is a critically important but commercially challenging area. Success here lies in successfully navigating regulatory hurdles and proving the value of a new antibiotic.
Market marginality as a whole
Iterum Therapeutics plc is a pharmaceutical company developing a new antibiotic for the treatment of infections caused by drug-resistant bacteria. This graph shows average profitability, but for ITRM, the growing threat of antibiotic resistance creates an urgent need for new drugs, which determines the market potential of its product.
Employees in the company, segment and market as a whole
Number of employees in the company Iterum Therapeutics plc
Iterum Therapeutics is a clinical-stage pharmaceutical company focused on antibiotics. This graph shows a very compact team. This structure is typical for a biotech company that outsources most clinical research, while its in-house staff handles project management and regulatory matters.
Share of the company's employees Iterum Therapeutics plc within the market segment - Pharma infections
Iterum Therapeutics is a pharmaceutical company focused on developing antibiotics to combat drug-resistant bacteria. This is a critically important area of medicine. This figure reflects its human capital's commitment to addressing one of the most serious threats to global health.
Number of employees in the market segment - Pharma infections
Iterum Therapeutics is a pharmaceutical company developing antibiotics to combat multidrug-resistant bacteria. This chart reflects employment in the infectious diseases sector. The growing number of microbiologists reflects the global concern about antibiotic resistance, creating a pressing need for new drugs like those being developed by Iterum.
Number of employees in the market as a whole
Iterum Therapeutics is a pharmaceutical company developing new antibiotics. Antibiotic resistance is a global problem. This chart shows the overall economic impact, but for Iterum, gaining regulatory approval and offering a solution to one of the most pressing healthcare challenges is more important.
Market capitalization per employee (in thousands of dollars) of the company, segment, and market as a whole
Market capitalization per employee (in thousands of dollars) of the company Iterum Therapeutics plc (ITRM)
Iterum Therapeutics plc is a pharmaceutical company developing antibiotics. Combating antibiotic resistance is a major challenge. The moderate or high market capitalization per employee in this chart will depend on the drug's development stage and the market's assessment of its chances of approval and commercial success.
%20of%20the%20company%20Iterum%20Therapeutics%20plc%20(ITRM)&width=1500&height=450&colorIndex=63&filename=GURU_Markets_-_Chart-of-market-capitalization-per-employee-in-thousands-of-dollars-of-the-company-Iterum-Therapeutics-plc-ITRM&v=1772671932951 "Chart of market capitalization per employee (in thousands of dollars) of the company Iterum Therapeutics plc (ITRM)")
Market capitalization per employee (in thousands of dollars) in the market segment - Pharma infections
Iterum Therapeutics plc is a pharmaceutical company focused on developing antibiotics to combat multidrug-resistant pathogens. In this critically important but complex area of pharmaceuticals, the cost per employee reflects the market valuation of their lead drug candidate, indicating confidence in their commercial and medical success.
%20by%20market%20segment%20-%20Pharma%20infections&width=1500&height=450&colorIndex=64&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-by-market-segment-Pharma-infections&v=1772671933017 "Market capitalization per employee (in thousands of dollars) by market segment - Pharma infections")
Market capitalization per employee (in thousands of dollars) for the overall market
Iterum Therapeutics plc is a pharmaceutical company developing a new antibiotic for the treatment of complex infections. With antibiotic resistance on the rise, their work is critical. The chart reflects how the market perceives the potential of their key drug.
%20for%20the%20overall%20market&width=1500&height=450&colorIndex=65&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-for-the-overall-market&v=1772671933054 "Market capitalization per employee (in thousands of dollars) for the overall market")
Profit per employee (in thousands of dollars) for the company, segment, and market as a whole
Profit per employee (in thousands of dollars) of the company Iterum Therapeutics plc (ITRM)
Iterum Therapeutics (ITRM) is a biopharmaceutical company specializing in developing oral antibiotics for the treatment of drug-resistant infections (superbugs). This graph (negative) shows R&D intensity. It measures how much capital the company is burning through per scientist in its quest to secure FDA approval for its much-needed but difficult-to-develop antibiotic.
%20Chart%20Iterum%20Therapeutics%20plc%20(ITRM)&width=1500&height=450&colorIndex=66&filename=GURU_Markets_-_Company-Profit-Per-Employee-in-thousands-of-dollars-Chart-Iterum-Therapeutics-plc-ITRM&v=1772671933111 "Company Profit Per Employee (in thousands of dollars) Chart Iterum Therapeutics plc (ITRM)")
Profit per employee (in thousands of dollars) in the market segment - Pharma infections
Iterum Therapeutics is a pharmaceutical company developing antibiotics to combat drug-resistant bacteria. Developing new antibiotics is a complex task that requires a highly effective scientific team. This chart shows the financial return on their research and provides a comparison with other companies working in this important field.
%20in%20the%20market%20segment%20-%20Pharma%20infections&width=1500&height=450&colorIndex=67&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-in-the-market-segment-Pharma-infections&v=1772671933137 "Chart of profit per employee (in thousands of dollars) in the market segment - Pharma infections")
Profit per employee (in thousands of dollars) for the market as a whole
Iterum Therapeutics (ITRM) is a pharmaceutical company developing antibiotics. The company is in the R&D stage. Negative profit per employee is the norm. The graph shows the "cost" of a team of scientists working on this socially significant but complex task of obtaining FDA approval.
%20for%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=68&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-for-the-market-as-a-whole&v=1772671933160 "Chart of profit per employee (in thousands of dollars) for the market as a whole")
Sales to employees of the company, segment and market as a whole
Sales per company employee Iterum Therapeutics plc (ITRM)
Iterum Therapeutics is a clinical-stage pharmaceutical company specializing in antibiotics. Its revenue is likely nonexistent at this stage. This timeline will only become relevant after the potential approval and launch of its drug to combat resistant bacterial infections.
&width=1500&height=450&colorIndex=69&filename=GURU_Markets_-_Sales-chart-per-company-employee-Iterum-Therapeutics-plc-ITRM&v=1772671933188 "Sales chart per company employee Iterum Therapeutics plc (ITRM)")
Sales per employee in the market segment - Pharma infections
Iterum Therapeutics is a pharmaceutical company developing an oral antibiotic (sulopenem) for the treatment of drug-resistant urinary tract infections. This chart compares Iterum's revenue per employee to the industry average. This demonstrates how productive their R&D and commercial efforts (if the drug is approved) are.
Sales per employee for the market as a whole
Iterum Therapeutics (ITRM) is a biotech company developing a new antibiotic (Sulopenem) for the treatment of complex infections. The company is in the late stage (awaiting FDA approval). The company has no commercial sales revenue. This graph will show $0, which is typical for R&D companies prior to approval.
Short shares by company, segment and market as a whole
Shares shorted by company Iterum Therapeutics plc (ITRM)
Iterum Therapeutics (ITRM) is a pharmaceutical company developing a new antibiotic. Their drug has been rejected by the FDA several times. This chart shows the number of investors who believe the company will never receive approval, or that even if successful, the drug will not be in demand.
&width=1500&height=450&colorIndex=72&filename=GURU_Markets_-_Short-Shares-Chart-for-the-Company-Iterum-Therapeutics-plc-ITRM&v=1772671933303 "Short Shares Chart for the Company Iterum Therapeutics plc (ITRM)")
Shares shorted by market segment - Pharma infections
Iterum Therapeutics (ITRM) is a pharmaceutical company developing a new oral antibiotic (Sulopenem) for the treatment of urinary tract infections. This chart shows the betting against the "anti-infectious" biotech sector. It reflects investor doubts that the company will receive FDA approval after previous failures.
Shares shorted by the overall market
Iterum Therapeutics is a biotech company developing new antibiotics. The company has faced FDA rejections. This chart illustrates the overall market pessimism. When investors are fearful, they are unforgiving of past failures. Rising fear means the company has no margin for error in new trials, and its shares are selling off.
RSI 14 indicator for a company, segment, and market as a whole
The company's RSI 14 indicator Iterum Therapeutics plc (ITRM)
Iterum Therapeutics is a single-product biotech (the antibiotic sulopenem). The company has been rejected by the FDA several times. This indicator clearly shows these binary events: "overbought" (above 70) on hopes before the FDA decision and a collapse into "oversold" (below 30) after the rejection.
&width=1500&height=450&colorIndex=75&filename=GURU_Markets_-_RSI-14-indicator-chart-for-the-companys-stock-Iterum-Therapeutics-plc-ITRM&v=1772671933431 "RSI 14 indicator chart for the company's stock Iterum Therapeutics plc (ITRM)")
RSI 14 Market Segment - Pharma infections
Iterum Therapeutics is a biopharmaceutical company developing antibiotics to treat infections caused by multidrug-resistant bacteria. This is an important but complex niche. This chart measures the overall momentum in the infectious disease biotech sector. It helps separate ITRM dynamics from the general industry hype.
RSI 14 for the overall market
Iterum (ITRM) is a biotech company. Like everything in its sector, it's critically dependent on this chart. Market euphoria is an easy way to raise hundreds of millions of dollars for research. Market panic is the risk of running out of money before its breakthrough technologies reach patients.
Analyst consensus forecast for the company's share price, the segment, and the market as a whole
Analyst consensus stock price forecast ITRM (Iterum Therapeutics plc)
Iterum Therapeutics (ITRM) is a biopharmaceutical company whose primary asset is Sulopenem, an oral antibiotic for the treatment of complex (resistant) urinary tract infections. This chart shows the speculative average price target from analysts, which is almost entirely dependent on their belief in the drug's FDA approval.
&width=1500&height=450&colorIndex=78&filename=GURU_Markets_-_A-chart-showing-analyst-consensus-forecasts-for-the-expected-stock-price.-ITRM-Iterum-Therapeutics-plc&v=1772671933471 "A chart showing analyst consensus forecasts for the expected stock price. ITRM (Iterum Therapeutics plc)")
The difference between the consensus estimate and the actual stock price ITRM (Iterum Therapeutics plc)
Iterum Therapeutics is an Irish biopharmaceutical company whose sole bet is *sulopenem*, an oral antibiotic for the treatment of drug-resistant infections. This chart shows the difference between the market valuation and the consensus estimate. It shows whether experts believe the drug will be approved by the FDA and has commercial potential.
&width=1500&height=450&colorIndex=79&filename=GURU_Markets_-_A-chart-showing-the-difference-between-the-consensus-forecast-and-the-actual-stock-price.-ITRM-Iterum-Therapeutics-plc&v=1772671933528 "A chart showing the difference between the consensus forecast and the actual stock price. ITRM (Iterum Therapeutics plc)")
Analyst consensus forecast for stock prices by market segment - Pharma infections
Iterum (ITRM) is a biopharmaceutical company developing a new oral antibiotic (Sulopenem) to combat "superbugs" (resistant infections). This chart shows general expectations for the pharmaceutical sector. It reflects whether experts believe new antibiotics will be commercially successful in a challenging market.
Analysts' consensus forecast for the overall market share price
Iterum Therapeutics (ITRM) is a biopharmaceutical company solving the problem of "superbugs." They are developing a new oral antibiotic for the treatment of complex urinary tract infections. This chart shows the overall risk appetite, reflecting the market's willingness to fund the complex and low-margin antibiotic development sector.
AKIMA index of the company, segment and market as a whole
AKiMA Company Index Iterum Therapeutics plc
Iterum Therapeutics is a one-bet biotech. Their entire fate hinges on a single drug: Sulopenem, an oral antibiotic for the treatment of complex urinary tract infections (UTIs). This chart is a summary indicator of their battle with the FDA. Its dynamics are all or nothing, depending entirely on their (previously unsuccessful) attempts to gain regulatory approval.
AKIMA Market Segment Index - Pharma infections
Iterum Therapeutics (ITRM) is a pharmaceutical company specializing in developing antibiotics to combat multidrug-resistant bacteria. Their lead candidate, Sulopenem, is designed to treat complex infections. The chart shows the average index for the segment, helping investors assess how Iterum's risks in the complex antibiotics space compare to the average.
The AKIM Index for the overall market
Iterum Therapeutics is a pharmaceutical company focused on developing oral antibiotics (sulopenem) for the treatment of drug-resistant infections. This chart, which reflects the market average, provides a macro backdrop. It helps assess how ITRM, while overcoming regulatory barriers, compares to overall economic trends.
